MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
TSI EDITOR |
2022-05-16
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
TSI EDITOR |
2022-05-17
Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.
TSI EDITOR |
2022-05-16
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
TSI EDITOR |
2022-05-16
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
TSI EDITOR |
2022-05-16
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
TSI EDITOR |
2022-05-16
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
TSI EDITOR |
2022-05-12
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
TSI EDITOR |
2022-05-12
Delic Holdings subsidiary, Ketamine Wellness Centers (KWC) announces a partnership with the Veterans Administration to provide ketamine-assisted therapy for veterans with PTSD.
TSI EDITOR |
2022-05-12
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
TSI EDITOR |
2022-05-12
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now